Cagrilintide is a protracted-acting amylin receptor agonist developed by Novo Nordisk for weight administration and metabolic health. It mimics the action of Normally developing amylin hormone, which happens to be co-secreted with insulin from pancreatic beta cells.By activating these receptors, cagrilintide additionally slows the speed of gastric